Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe study record now shows that recruitment is no longer open to participants, indicating that enrollment is closed. New reader guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment locations were updated to reflect Sariyer, Turkey, with a prior location removed, signaling changes to how participants can locate sites.SummaryDifference0.2%

- Check8 days agoChange DetectedThe revision tag in the page footer was updated from v3.5.4 to v3.5.5. This signals a minor behind-the-scenes update to the site.SummaryDifference0.0%

- Check15 days agoChange DetectedLocation data for a site in Ukraine was updated to use the official Kharkiv Oblast designation. The address line now reads Kharkiv, Kharkiv Oblast, Ukraine, 61070, replacing the previous Kharkivs’ka Oblast’ variant.SummaryDifference0.0%

- Check22 days agoChange DetectedA new publication reference has been added under Publications, citing a 2026 J Clin Oncol article about selpercatinib and postprogression therapies. This update enriches the study record with additional related literature tied to the trial.SummaryDifference0.0%

- Check29 days agoChange DetectedThe page’s revision label was updated from v3.5.3 to v3.5.4, reflecting a small maintenance update to the page metadata.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study location entry for Bucharest has been updated to use an alternate spelling/formatting (removing diacritics and standardizing the text). The page also reflects an updated revision/version label.SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.